

AMENDMENTS TO THE CLAIMS

This listing of the Claims will replace all prior versions, and listings, of the claims in the application:

1-17. (canceled)

18. (currently amended) A method for producing an isotransgenic maize line, as compared to a maize line that is recalcitrant or unsuited to transformation and has a transformation efficiency of zero to 1/100, comprising:

a) transforming cells of a hybrid plant, the parental lines of which are a maize line of interest that is recalcitrant or unsuited to transformation and has a transformation efficiency of zero to 1/100 and a maize line suited to transformation, with a vector comprising a T-DNA containing a transgene in order to obtain hybrid primary transformants, wherein said maize line suited to transformation is chosen from the group consisting of ~~comprising~~ A188 and Hi-11 maize lines;

b) selecting for at least one individual among said hybrid primary transformants which has said T-DNA integrated only into the genome of said line of interest, in order to obtain selected individual(s), wherein said selection is performed by isolation and identification of genomic sequences of the host adjacent to the T-DNA, ~~using Restriction Fragment Length Polymorphism~~;

c) backcrossing said the individual(s) selected in step b) with an individual of said parental maize line of interest; and

d) selecting at least one transgenic individual obtained from the backcross in step c;

e) repeating steps c and d until said isotransgenic maize line is produced.

19-22 (canceled).

23. (previously presented) The method of Claim 18 further comprising crossing said isotransgenic maize line obtained in step e) and a second line of interest.

24. (previously presented) The method of Claim 18, wherein said transgene encodes a protein which confers agronomic properties and/or properties of resistance to diseases.

25. (previously presented) The method of Claim 18, wherein said line of interest is a commercial elite line.

26. (canceled)

27. (previously presented) The method of Claim 23, wherein the second line of interest is an isotransgenic plant line.